Halozyme Therapeutics, Inc.
Description
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
About
CEO
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Employees
373
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNGS
Address
12390 El Camino Real, San Diego, CA 92130, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Oct 29, 2025 | — | — | — | — |
| Aug 4, 2025 | — | — | — | — |
| May 5, 2025 | — | — | — | — |
| Feb 18, 2025 | 1.17 | — | — | — |
| Nov 1, 2024 | 0.98 | 1.27 | 0.29 | 29.59% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 5 | — | 5 |
| Average estimate | — | 0.97 | — | 5.05 |
| Low estimate | — | 0.85 | — | 4.63 |
| High estimate | — | 1.08 | — | 5.25 |
| Last year EPS | — | 0.79 | — | 4.13 |
[stock_revenue_estimate]
Growth estimates
Current qtr
41.320%
Next qtr. (Mar 2025)
23.040%
Current year
49.020%
Next year (Dec 2025)
22.410%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 829.25M | 660.12M | 443.31M | 267.59M | 195.99M |
| Cost of revenue | 192.36M | 139.30M | 81.41M | 43.37M | 45.55M |
| Gross profit | 636.89M | 520.81M | 361.90M | 224.23M | 150.45M |
| Operating expense | |||||
| Research & development | 76.36M | 66.61M | 35.67M | 34.24M | 140.80M |
| Selling general and admin | 149.18M | 143.53M | 50.32M | 45.74M | 77.25M |
| Other operating expenses | — | — | — | — | — |
| Operating income | 337.57M | 267.53M | 275.90M | 144.26M | -67.61M |
| Non operating interest income | |||||
| Income | — | — | — | — | — |
| Expense | 18.76M | 16.95M | 7.53M | 20.38M | 11.63M |
| Other income expense | 29.52M | -1.67M | -19.86M | 5.43M | 6.99M |
| Pretax income | 348.33M | 248.92M | 248.52M | 129.30M | -72.25M |
| Tax provision | 66.74M | 46.79M | -154.19M | 217,000 | -11,000 |
| Net income | 281.59M | 202.13M | 402.71M | 129.09M | -72.24M |
| Basic EPS | 2.13 | 1.48 | 2.86 | 0.95 | -0.50 |
| Diluted EPS | 2.10 | 1.44 | 2.74 | 0.91 | -0.50 |
| Basic average shares | 131.93M | 136.84M | 140.65M | 136.21M | 144.33M |
| Diluted average shares | 131.93M | 136.84M | 140.65M | 136.21M | 144.33M |
| EBITDA | 422.43M | 317.17M | 278.90M | 147.54M | -63.54M |
| Net income from continuing op. | 281.59M | 202.13M | 402.71M | 129.09M | -72.24M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 1.73B | 1.84B | 1.10B | 579.92M | 565.87M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 118.37M | 234.20M | 118.72M | 147.70M | 120.18M |
| Other short term investments | 217.63M | 128.60M | 622.20M | 220.31M | 301.08M |
| Accounts receivable | 240.00M | 188.88M | 92.12M | 98.73M | 60.24M |
| Other receivables | 956,000 | 44.10M | — | — | — |
| Inventory | 127.60M | 100.12M | 53.91M | 60.75M | 29.36M |
| Prepaid assets | — | — | 40.48M | 28.27M | 33.37M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 48.61M | 45.02M | 40.48M | 28.27M | 33.37M |
| Non current assets | |||||
| Properties | 77.90M | 75.74M | 14.90M | 15.72M | 15.11M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 9.72M | 7.86M | 5.37M | 4.83M | 4.86M |
| Construction in progress | — | — | — | — | — |
| Leases | 6.99M | 6.73M | 1.63M | 1.63M | 1.63M |
| Accumulated depreciation | -19.66M | -14.76M | -13.10M | -11.58M | -10.74M |
| Goodwill | 1.31B | 1.36B | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 472.88M | 546.65M | — | — | — |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 22.20M | 71.23M | 169.35M | 14.57M | 11.58M |
| Total liabilities | 1.65B | 1.67B | 907.48M | 428.88M | 474.11M |
| Current liabilities | |||||
| Accounts payable | 11.82M | 17.69M | 1.54M | 1.93M | 6.43M |
| Accrued expenses | 100.68M | 99.76M | 24.44M | 20.48M | 55.65M |
| Short term debt | — | 13.33M | 89.42M | 397.23M | 19.54M |
| Deferred revenue | — | 3.25M | 1.75M | 1.75M | 4.01M |
| Tax payable | — | — | — | — | — |
| Pensions | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — |
| Non current liabilities | |||||
| Long term debt | 1.50B | 1.49B | 787.26M | — | 383.05M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 37.72M | 48.16M | 544,000 | 3.47M | 4.18M |
| Shareholders equity | |||||
| Common stock | 127,000 | 135,000 | 138,000 | 135,000 | 137,000 |
| Retained earnings | 90.55M | 143.22M | -58.91M | -474.59M | -603.68M |
| Other shareholders equity | -9.28M | -922,000 | -620,000 | 22,000 | 240,000 |
| Total shareholders equity | 83.81M | 169.80M | 196.95M | 151.05M | 91.77M |
| Additional paid in capital | 2.41M | 27.37M | 256.35M | 625.48M | 695.07M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||||
| Net Income | 281.59M | 202.13M | 402.71M | 129.09M | -72.24M | -80.33M | 62.97M | -103.02M | -32.23M | -68.38M | -83.48M | -53.55M | -19.77M | -53.24M | -58.36M | -48.65M | -23.90M | -14.75M | -13.28M | -9.09M | -79,091 | -65,263 | -39,652 |
| Depreciation | 84.86M | 49.64M | 3.00M | 3.28M | 4.07M | 2.39M | 2.16M | 2.41M | 1.68M | 1.76M | 1.23M | 1.08M | 1.10M | 1.51M | 1.44M | 1.05M | 576,491 | 243,999 | 206,348 | 123,350 | — | — | — |
| Deferred Taxes | 34.51M | 40.01M | -155.43M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 36.62M | 24.40M | 20.82M | 17.20M | 34.78M | 35.70M | 30.67M | 25.59M | 20.84M | 15.27M | 9.54M | 8.35M | 5.57M | 4.87M | 4.53M | 3.70M | — | — | — | — | — | — | — |
| Other Non-Cash Items | -4.63M | 6.93M | 22.35M | 13.60M | -1.98M | 1.70M | 17.82M | -5.53M | 877,000 | 3.50M | 156,000 | 9,000 | — | — | — | 3.70M | 2.58M | 1.28M | — | — | 2,340 | 2,340 | 1,990 |
| Accounts Receivable | -3.34M | -83.94M | 6.76M | -38.29M | -29.44M | 11.61M | -6.45M | 16.73M | -23.26M | -52,000 | 6.61M | -13.44M | 65,803 | 1.92M | 3.02M | -6.48M | -416,260 | -119,558 | -391,669 | — | — | — | — |
| Accounts Payable | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | -26.88M | -17.48M | 7.37M | -31.39M | -6.73M | -17.48M | 9.48M | -5.13M | -4.33M | 1.24M | 5.65M | 954,000 | -17.36M | -1.74M | 10.20M | 10.80M | 19.89M | 19.56M | 27,002 | -51,821 | — | — | — |
| Operating Cash Flow | 402.73M | 221.68M | 307.57M | 93.50M | -71.55M | -46.42M | 116.65M | -68.96M | -36.43M | -46.65M | -60.30M | -56.60M | -30.40M | -46.69M | -39.17M | -35.89M | -1.26M | 6.22M | -13.43M | -9.02M | -76,751 | -62,923 | -37,662 |
| Investing Activities | |||||||||||||||||||||||
| Capital Expenditures | -15.29M | -4.81M | -1.46M | -1.43M | -4.04M | -4.66M | -1.35M | -3.14M | -2.36M | -1.37M | -2.30M | -1.41M | -828,508 | -646,544 | -1.46M | -1.16M | -2.37M | -364,799 | -350,891 | -227,951 | — | — | — |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | -999.12M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | -292.91M | -255.21M | -652.52M | -226.19M | -389.76M | -311.11M | -398.19M | -155.41M | -71.48M | -88.88M | -48.95M | — | — | — | — | — | — | — | — | — | — | — | — |
| Sale of Investments | 211.30M | 746.13M | 247.68M | 305.97M | 388.25M | 318.27M | 235.81M | 81.78M | 79.73M | 57.30M | 3.38M | — | — | — | — | — | — | — | — | — | — | — | — |
| Investing Cash Flow | -96.91M | -487.01M | -406.29M | 78.35M | -5.55M | 2.49M | -163.73M | -76.77M | 5.89M | -32.95M | -47.87M | -1.41M | -828,508 | -646,544 | -1.46M | -1.16M | -2.37M | -364,799 | -350,891 | -227,951 | — | — | — |
| Financing Activities | |||||||||||||||||||||||
| Long-Term Debt Issuance | — | 1.07B | 784.88M | — | 447.35M | — | — | 203.01M | — | — | 19.99M | 29.66M | — | — | — | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | -13.48M | -447.45M | -369.06M | -19.56M | -108.08M | -77.52M | -16.00M | -54.25M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | — | -76.22M | -424,000 | — | -279,000 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 7.87M | — | — | — |
| Financing Cash Flow | -415.87M | 348.32M | 65.33M | -169.68M | 138.99M | -77.52M | 118.88M | 148.76M | — | 107.71M | 19.99M | 111.14M | — | 59.97M | 38.17M | — | 56.00M | 18.34M | 16.47M | 23.45M | — | 126,900 | 60,500 |
| Other Cash Details | |||||||||||||||||||||||
| End Cash Position | 118.37M | 234.70M | 119.22M | 148.20M | 120.68M | 58.44M | 169.24M | 67.26M | 43.79M | 61.39M | 27.36M | 99.50M | 52.38M | 83.26M | 67.46M | 63.72M | 97.68M | 44.19M | 19.13M | 16.01M | 47,517 | 97,249 | 26,127 |
| Income Tax Paid | 31.76M | 16.22M | — | 180,000 | 188,000 | 220,000 | 3.02M | 1.44M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | 11.41M | 6.11M | 3.30M | 6.53M | 9.03M | 16.89M | 20.30M | 3.89M | 3.78M | 3.46M | 3.10M | 19,000 | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | 373.28M | 235.30M | 297.98M | 52.95M | -89.46M | -54.16M | 132.70M | -53.52M | -39.44M | -48.89M | -51.64M | -65.69M | -35.13M | -46.03M | -41.61M | -36.53M | -2.51M | 6.71M | -13.35M | -7.95M | -49,732 | -55,778 | -34,373 |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| iShares Core S&P Midcap ETF | Nov 30, 2024 | 4,068,392 | 230.96M | 3.20% |
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 4,034,236 | 229.02M | 3.17% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 3,487,131 | 197.96M | 2.74% |
| Vanguard Small-Cap Index Fund | Sep 30, 2024 | 3,171,433 | 180.04M | 2.49% |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | Nov 30, 2024 | 2,026,522 | 115.05M | 1.59% |
| Vanguard Explorer Fund, Inc. | Oct 31, 2024 | 1,969,364 | 111.80M | 1.55% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 1,894,447 | 107.55M | 1.49% |
| Vanguard Small-Cap Growth Index Fund | Sep 30, 2024 | 1,748,667 | 99.27M | 1.37% |
| Delaware Group Equity Fds V-Small Cap Core Fund | Nov 30, 2024 | 1,738,500 | 98.69M | 1.37% |
| Artisan Small Cap Fund | Sep 30, 2024 | 1,306,823 | 74.19M | 1.03% |
Article
Halozyme Stock Climbs Back After 2024 Sneak Peak As Earnings Loom
This biotech stock is recovering from a severe drop in November after the company raised its 2025 guidance. The post Halozyme Stock Climbs Back After 2024 Sneak Peak As Earnings Loom appeared first on Investor's Business Daily.
Feb 6, 2025
Article
Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results
SAN DIEGO , Feb. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2024 financial and operating results on Tuesday, February 18, 2025, following the close of trading. Halozyme will host a conference call on Tuesday, February 18, 2025 at 1:30 p.m.
Feb 4, 2025
Article
CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
SAN DIEGO , Feb. 3, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommending an extension of marketing authorisation for a subcutaneous (SC) formulation of RYBREVANT® (amivantamab) in combination with LAZCLUZE® (lazertinib) for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, and as a monotherapy for the treatment of adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations after failure of platinum-based therapy. "We are pleased that the subcutaneous formulation of amivantamab, which was developed with our ENHANZE drug delivery technology, was recommended for approval in Europe," said Dr. Helen Torley, president and chief executive officer of Halozyme.
Feb 3, 2025
